171 related articles for article (PubMed ID: 12142815)
1. Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis.
Francisco MP; Wagner MH; Sherman JM; Theriaque D; Bowser E; Novak DA
J Pediatr Gastroenterol Nutr; 2002 Jul; 35(1):79-83. PubMed ID: 12142815
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
[TBL] [Abstract][Full Text] [Related]
3. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT.
Van de Vijver E; Desager K; Mulberg AE; Staelens S; Verkade HJ; Bodewes FA; Malfroot A; Hauser B; Sinaasappel M; Van Biervliet S; Behm M; Pelckmans P; Callens D; Veereman-Wauters G
J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):61-4. PubMed ID: 21694537
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
[TBL] [Abstract][Full Text] [Related]
5. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study.
Brady MS; Garson JL; Krug SK; Kaul A; Rickard KA; Caffrey HH; Fineberg N; Balistreri WF; Stevens JC
J Am Diet Assoc; 2006 Aug; 106(8):1181-6. PubMed ID: 16863712
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.
Trapnell BC; Maguiness K; Graff GR; Boyd D; Beckmann K; Caras S
J Cyst Fibros; 2009 Dec; 8(6):370-7. PubMed ID: 19815466
[TBL] [Abstract][Full Text] [Related]
7. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency.
Wooldridge JL; Heubi JE; Amaro-Galvez R; Boas SR; Blake KV; Nasr SZ; Chatfield B; McColley SA; Woo MS; Hardy KA; Kravitz RM; Straforini C; Anelli M; Lee C
J Cyst Fibros; 2009 Dec; 8(6):405-17. PubMed ID: 19683970
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
Graff GR; McNamara J; Royall J; Caras S; Forssmann K
Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
[TBL] [Abstract][Full Text] [Related]
9. Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis.
Kalnins D; Ellis L; Corey M; Pencharz PB; Stewart C; Tullis E; Durie PR
J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):256-61. PubMed ID: 16540792
[TBL] [Abstract][Full Text] [Related]
10. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis.
Safdi M; Bekal PK; Martin S; Saeed ZA; Burton F; Toskes PP
Pancreas; 2006 Aug; 33(2):156-62. PubMed ID: 16868481
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic enzyme replacement therapy. Importance of gastric acid secretion, H2-antagonists, and enteric coating.
Marotta F; O'Keefe SJ; Marks IN; Girdwood A; Young G
Dig Dis Sci; 1989 Mar; 34(3):456-61. PubMed ID: 2563963
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients.
Gan KH; Heijerman HG; Geus WP; Bakker W; Lamers CB
Aliment Pharmacol Ther; 1994 Dec; 8(6):603-7. PubMed ID: 7696449
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes.
Proesmans M; De Boeck K
Eur J Pediatr; 2003 Nov; 162(11):760-3. PubMed ID: 13680386
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection.
Jeppesen PB; Staun M; Tjellesen L; Mortensen PB
Gut; 1998 Dec; 43(6):763-9. PubMed ID: 9824602
[TBL] [Abstract][Full Text] [Related]
15. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.
Peghini PL; Katz PO; Castell DO
Gastroenterology; 1998 Dec; 115(6):1335-9. PubMed ID: 9834259
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of lower than standard doses of pancreatic enzyme supplementation therapy during acid inhibition in patients with pancreatic exocrine insufficiency.
Vecht J; Symersky T; Lamers CB; Masclee AA
J Clin Gastroenterol; 2006 Sep; 40(8):721-5. PubMed ID: 16940886
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis.
Toskes PP; Secci A; Thieroff-Ekerdt R;
Pancreas; 2011 Apr; 40(3):376-82. PubMed ID: 21343835
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effectiveness of pancreatic enzyme preparations in cystic fibrosis.
Mischler EH; Parrell S; Farrell PM; Odell GB
Am J Dis Child; 1982 Dec; 136(12):1060-3. PubMed ID: 7148760
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis.
Trapnell BC; Strausbaugh SD; Woo MS; Tong SY; Silber SA; Mulberg AE; Leitz G
J Cyst Fibros; 2011 Sep; 10(5):350-6. PubMed ID: 21632288
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.
Colombo C; Fredella C; Russo MC; Faelli N; Motta V; Valmarana L; Longo L; D'Orazio C
Pancreas; 2009 Aug; 38(6):693-9. PubMed ID: 19531972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
